MP 201

Drug Profile

MP 201

Alternative Names: MP201

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitochon Pharmaceuticals
  • Class Antiparkinsonians; Eye disorder therapies; Nitro compounds; Nootropics; Small molecules
  • Mechanism of Action Brain-derived neurotrophic factor expression modulators; Mitochondrial protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple sclerosis; Optic neuritis; Parkinson's disease

Most Recent Events

  • 18 Oct 2017 Pharmacodynamics data from a preclinical trial in Multiple Scleroris released by Mitochon Pharmaceuticals
  • 16 Oct 2017 Preclinical trials in Multiple sclerosis in USA (PO) before October 2017
  • 16 Oct 2017 Preclinical trials in Optic neuritis in USA (PO) before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top